公开(公告)号：US11305012B2

公开(公告)日：2022-04-19

申请号：US15023858

申请日：2014-09-23

Applicant: MedImmune, LLC

Inventor： Partha S. Chowdhury ,  David Tice ,  Zhan Xiao ,  Philipp Steiner ,  Krista Kinneer ,  Marlon Rebelatto ,  Andrew Pierce

IPC: A61K39/395 ,  C07K16/30 ,  C07K16/32 ,  A61K47/68 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

公开(公告)号：US20160237162A1

公开(公告)日：2016-08-18

申请号：US15023858

申请日：2014-09-23

Applicant: MEDIMMUNE, LLC

Inventor： Partha S. Chowdhury ,  David Tice ,  Zhan Xiao ,  Philipp Steiner ,  Krista Kinneer ,  Marlon Rebelatto ,  Andrew Pierce

IPC: C07K16/30 ,  A61K45/06 ,  A61K47/48 ,  C07K16/28 ,  A61K39/395

CPC classification number: C07K16/30 ,  A61K39/3955 ,  A61K39/39558 ,  A61K39/39591 ,  A61K45/06 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2863 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

Abstract translation: 本文提供了结合HER3受体的细胞外结构域的抗体及其抗原结合片段，并通过配体依赖和/或配体非依赖性机制抑制各种HER3受体相关功能。 还提供了具有增加的半衰期的组合物，以及用于诊断和治疗与HER3介导的信号转导相关的疾病的组合物和方法。

公开(公告)号：US20160159913A1

公开(公告)日：2016-06-09

申请号：US14947865

申请日：2015-11-20

Applicant: MedImmune LLC

Inventor： Partha S. Chowdhury ,  David Tice ,  Zhan Xiao ,  Philipp Steiner ,  Krista Kinneer ,  Marlon Rebelatto

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K45/06 ,  C07K16/40

CPC classification number: C07K16/2863 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  A61K2300/00

Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

Abstract translation: 本发明涉及结合HER3受体的细胞外结构域的抗体及其抗原结合片段，并通过配体依赖性和/或配体非依赖性机制抑制各种HER3受体相关功能。 还提供了具有增加的半衰期的组合物。 此外，本发明提供用于诊断和治疗与HER3介导的信号转导相关的疾病的组合物和方法。

公开(公告)号：US11912782B2

公开(公告)日：2024-02-27

申请号：US17215479

申请日：2021-03-29

Applicant: MedImmune, LLC

Inventor： Krista Kinneer ,  Reena Varkey ,  Xiaodong Xiao ,  Elaine M. Hurt ,  David Tice

IPC: C07K16/30 ,  C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K31/202 ,  A61K31/4741 ,  A61K31/551 ,  A61K31/7048 ,  C12N15/62 ,  A61K39/00

CPC classification number: C07K16/3061 ,  A61K31/202 ,  A61K31/4741 ,  A61K31/551 ,  A61K31/7048 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6867 ,  A61P35/00 ,  C07K16/2878 ,  C12N15/62 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92

Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.

公开(公告)号：US20140363429A1

公开(公告)日：2014-12-11

申请号：US14359864

申请日：2012-11-20

Applicant: MedImmune LLC

Inventor： Partha S. Chowdhury ,  David Tice ,  Zhan Xiao ,  Philipp Steiner ,  Krista Kinneer ,  Marlon Rebelatto

IPC: A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/57492 ,  A61K2300/00

Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

Abstract translation: 本发明涉及结合HER3受体的细胞外结构域的抗体及其抗原结合片段，并通过配体依赖性和/或配体非依赖性机制抑制各种HER3受体相关功能。 还提供了具有增加的半衰期的组合物。 此外，本发明提供用于诊断和治疗与HER3介导的信号转导相关的疾病的组合物和方法。

公开(公告)号：US20190040143A1

公开(公告)日：2019-02-07

申请号：US16024391

申请日：2018-06-29

Applicant: MedImmune, LLC

Inventor： Partha S. Chowdhury ,  David Tice ,  Zhan Xiao ,  Philipp Steiner ,  Krista Kinneer ,  Marlon Rebelatto

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  G01N33/574 ,  C07K16/30 ,  C07K16/40 ,  C07K16/32 ,  A61K39/00

Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.

公开(公告)号：US20240294666A1

公开(公告)日：2024-09-05

申请号：US18414892

申请日：2024-01-17

Applicant: MedImmune, LLC

Inventor： Krista Kinneer ,  Reena Varkey ,  Xiaodong Xiao ,  Elaine M Hurt ,  David Tice

IPC: C07K16/30 ,  A61K31/202 ,  A61K31/4741 ,  A61K31/551 ,  A61K31/7048 ,  A61K39/00 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28 ,  C12N15/62

CPC classification number: C07K16/3061 ,  A61K31/202 ,  A61K31/4741 ,  A61K31/551 ,  A61K31/7048 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6867 ,  A61P35/00 ,  C07K16/2878 ,  C12N15/62 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92

Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.

公开(公告)号：US10988546B2

公开(公告)日：2021-04-27

申请号：US16050944

申请日：2018-07-31

Applicant: MedImmune, LLC

Inventor： Krista Kinneer ,  Reena Varkey ,  Xiaodong Xiao ,  Elaine M. Hurt ,  David Tice

IPC: C07K16/30 ,  C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K31/202 ,  A61K31/4741 ,  A61K31/551 ,  A61K31/7048 ,  C12N15/62 ,  A61K39/00

Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.

公开(公告)号：US10040857B2

公开(公告)日：2018-08-07

申请号：US14947865

申请日：2015-11-20

Applicant: MedImmune, LLC

Inventor： Partha S. Chowdhury ,  David Tice ,  Zhan Xiao ,  Philipp Steiner ,  Krista Kinneer ,  Marlon Rebelatto

IPC: C07K16/32 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  G01N33/574 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.